Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...
Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...
Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a ...
Septerna (SEPN), which is developing a treatment for hypoparathyroidism, has proposed terms for an upsized $175M initial ...
Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...
The gross proceeds from the offering are expected to be $288.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on ...
Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, ...
Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...